Back to Search
Start Over
Renal Dysfunction and In‐Hospital Outcomes in Patients With Acute Ischemic Stroke After Intravenous Thrombolytic Therapy
Renal Dysfunction and In‐Hospital Outcomes in Patients With Acute Ischemic Stroke After Intravenous Thrombolytic Therapy
- Source :
- Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
- Publication Year :
- 2019
- Publisher :
- John Wiley and Sons Inc., 2019.
-
Abstract
- Background The impact of estimated glomerular filtration rate ( eGFR ) on clinical short‐term outcomes after stroke thrombolysis with tissue plasminogen activator remains controversial. Methods and Results We analyzed 18 320 ischemic stroke patients who received intravenous tissue plasminogen activator at participating hospitals in the Chinese Stroke Center Alliance between June 2015 and November 2017. Multivariate logistic regression models were used to evaluate associations between eGFR (2 ) and in‐hospital mortality and symptomatic intracerebral hemorrhage, adjusting for patient and hospital characteristics and the hospital clustering effect. Of the 18 320 patients receiving tissue plasminogen activator, 601 (3.3%) had an eGFR eGFR 45 to 59, 3679 (20.1%) had an eGFR 60 to 89, and 13 415 (73.2%) had an eGFR ≥90. As compared with eGFR ≥90, eGFR values CI , 2.18–5.91), 45 to 59 (4.0% versus 0.9%, adjusted odds ratio, 2.00; 95% CI , 1.18–3.38), and 60 to 89 (2.5% versus 0.9%, adjusted odds ratio, 1.67; 95% CI , 1.20–2.34) were independently associated with increased odds of in‐hospital mortality. However, there was no statistically significant association between eGFR and symptomatic intracerebral hemorrhage. Conclusions eGFR was associated with an increased risk of in‐hospital mortality in acute ischemic stroke patients after treatment with tissue plasminogen activator. eGFR is an important predictor of poststroke short‐term death but not of symptomatic intracerebral hemorrhage.
- Subjects :
- tissue‐type plasminogen activator
Male
medicine.medical_specialty
China
Renal function
Tissue plasminogen activator
Brain Ischemia
Brain ischemia
Internal medicine
medicine
ischemic stroke
Humans
In patient
Thrombolytic Therapy
Hospital Mortality
Registries
Infusions, Intravenous
Survival rate
Acute ischemic stroke
Original Research
Aged
Retrospective Studies
Aged, 80 and over
glomerular filtration rate
Quality and Outcomes
Dose-Response Relationship, Drug
business.industry
renal function
Retrospective cohort study
Middle Aged
medicine.disease
Stroke
Survival Rate
Treatment Outcome
Hospital outcomes
Tissue Plasminogen Activator
Acute Disease
Cardiology
outcome
Cerebrovascular Disease/Stroke
Female
Kidney Diseases
Cardiology and Cardiovascular Medicine
business
medicine.drug
Subjects
Details
- Language :
- English
- ISSN :
- 20479980
- Volume :
- 8
- Issue :
- 20
- Database :
- OpenAIRE
- Journal :
- Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
- Accession number :
- edsair.doi.dedup.....61baa4a18279de317717034acb16d1cb